Event Panel Schedule
TBA
Clinical Insights of New Rapidly Acting, NMDA-based Antidepressants

Robert Eric Besthof , CMO / NeuroRx
Mr. Robert Besthof serves as Chief Commercial Officer at NeuroRx. He is a global biopharmaceutical executive with a 25+year career covering global pipeline & country operational marketing & sales roles. He has managed numerous specialty…
TBA
NK cell expansion and proliferation with PM21 particles: adjunctive therapy for hematopoietic stem cell transplantation and potential treatment for both liquid and solid tumors


Arthur Lahr , CEO / Kiadis Pharma N.V.
Arthur Lahr is Chief Executive Officer of Kiadis Pharma. Prior to joining Kiadis Pharma, he was Chief Strategy Officer and member of the Management Committee at Crucell from 2001 until its acquisition by Johnson & Johnson in 2011. Before that he…
TBA
Three clinical-stage cell therapy programs in dry age-related macular degeneration, spinal cord injury, and oncology


Brian Culley , CEO/Interim CFO / Lineage Cell Therapeutics Inc.
Mr. Culley joined Lineage Cell Therapeutics as CEO in September 2018. Prior to joining Lineage Cell Therapeutics, Mr. Culley served from August 2017 to September 17, 2018 as Interim Chief Executive Officer at Artemis Therapeutics, Inc., a, where he…
TBA
SCLC: Recent approvals in first and third line could be joined with Lurbinectedin in 2nd line


Pascal Besman , Chief Operating Officer (PharmaMar U.S.) / PharmaMar SA
Prior to joining JMP, Pascal was a partner and institutional salesperson at Maxim and also ThinkEquity for three years. He previously served as a senior vice president at UBS and has held equity sales positions at Bear Stearns, Lehman Brothers and…
TBA
Oncolytic adenovirus armed w immune stimulating transgene targeting basket of I-O indications


Torbjørn Furuseth , Chief Financial Officer / Targovax
An experienced executive with a broad background within life science. He joins from the clinical stage immune-oncology company Lytix Biopharma, where he has served as CFO and conducted several financing rounds. Prior to this, he was EVP Innovation at…
TBA
E-CEL® (Engineered Endothelial Cell) Therapy and Vascular Niche Biology


Paul Finnegan , CEO / Angiocrine Bioscience
Dr. Finnegan is Chief Executive Officer of Angiocrine Bioscience. He has more than 20 years of life science management experience in the biotechnology, pharmaceutical, and healthcare industries